04-Nov-2026 17:41:04
NOVARTIS INDIA (NOW EVONILE PHARMA) Q2 FY27 CONCALL: TARGETS ₹150 CR QUARTERLY REVENUE RUN RATE BY Q4 FY27/Q1 FY28, ₹600+ CR FY28 REVENUE & ORGANIC REVENUE DOUBLING IN 5–6 YEARS; PLANS DEBT REDUCTION BY MARCH 2027
NOVARTIS INDIA (NOW EVONILE PHARMA) Q2 FY27 CONCALL: TARGETS ₹150 CR QUARTERLY REVENUE RUN RATE BY Q4 FY27/Q1 FY28, ₹600+ CR FY28 REVENUE & ORGANIC REVENUE DOU…